资金流向方面，主力资金净流入146.07万元，特大单买入0.00元，占比0.00%，卖出104.81万元，占比 1.78%；大单买入1234.20万元，占比20.98%，卖出983.32万元，占比16.72%。 10月10日，金石亚药盘中上涨2.00%，截至14:27，报9.68元/股，成交5882.58万元，换手率1.79%，总市 值38.89亿元。 金石亚药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：医药电商、抗流感、中 药、零售药店、生物医药等。 截至6月30日，金石亚药股东户数2.28万，较上期增加14.00%；人均流通股15010股，较上期减少 12.28%。2025年1月-6月，金石亚药实现营业收入4.92亿元，同比减少5.80%；归母净利润6574.54万元， 同比增长67.71%。 分红方面，金石亚药A股上市后累计派现1.70亿元。近三年，累计派现7191.22万元。 责任编辑：小浪快报 金石亚药今年以来股价涨18.32%，近5个交易日涨0.73%，近20日跌3.49%，近60日跌3.39%。 今年以来金石亚药已经1次登上龙虎榜，最近一次登上龙虎榜为1月6日，当日龙虎榜净买 ...

10月10日，康弘药业盘中下跌2.02%，截至14:13，报35.92元/股，成交1.06亿元，换手率0.42%，总市值 330.94亿元。 资金流向方面，主力资金净流出117.29万元，特大单买入260.92万元，占比2.47%，卖出201.25万元，占 比1.90%；大单买入1200.69万元，占比11.36%，卖出1377.64万元，占比13.03%。 康弘药业今年以来股价涨89.05%，近5个交易日跌2.79%，近20日跌8.72%，近60日涨23.48%。 截至9月30日，康弘药业股东户数2.40万，较上期减少3.67%；人均流通股28624股，较上期增加3.81%。 2025年1月-6月，康弘药业实现营业收入24.54亿元，同比增长6.95%；归母净利润7.30亿元，同比增长 5.41%。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，康弘药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2727.50万股，相比上期减少531.59万股。大成睿享混合A（008269）位居第六大流通股 东，持股1225. ...

Core Viewpoint - Kanghong Pharmaceutical has shown significant stock performance with a year-to-date increase of 95.79%, despite a recent decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, up 5.41% year-on-year [2]. Stock Market Activity - As of September 30, the stock price of Kanghong Pharmaceutical was 37.20 yuan per share, with a market capitalization of 34.273 billion yuan. The stock experienced a trading volume of 163 million yuan and a turnover rate of 0.65% [1]. - The stock has seen a net outflow of 1.1269 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of September 19, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, with an average of 27,573 circulating shares per person, a decrease of 0.74% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]

海南省药品监督管理局关于依法注销海南天诺药业有限公司等3家企业 《药品经营许可证》的公告（2025年第5号） 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》和《药品经营和使用质量监督管理办法》等有关规定，海南省药品监督管理局 依法注销海南天诺药业有限公司、海南洋浦君和医药有限公司、国药控股专业药房连锁（海南）有限公司的《药品经营许可证》。自注销之日起，该企业须 立即停止药品经营活动，请社会各界监督。 | 企业名称 | 经营地址 | 仓库地址 | 经营范围 | 许可证编号 | 备 注 | | --- | --- | --- | --- | --- | --- | | | | | | | 企 | | | | | | | 业 | | | | 海南省海口市金盘工业开发 | | | 主 | | 海南天诺药业 | 海口市世贸东路2号世贸雅苑 | 区建设路10号（国药控股海 | 中成药、化学药（含原料药）、生物制品（以上不含冷藏、 | 琼 | 动 | | 有限公司 | G座第21层22B1房、22B2房 | 南有限公司仓库） | 冷冻药品）*** | AA898000025 | 申 | | | | | ...

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 96.63% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of September 24, Kanghong Pharmaceutical's stock price was 37.36 CNY per share, with a market capitalization of 34.42 billion CNY [1]. - The stock experienced a net inflow of 5.30 million CNY from main funds, with large orders accounting for 13.33% of purchases [1]. - The stock has seen a 5.70% decline over the last five trading days and an 8.27% decline over the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.45 billion CNY, representing a year-on-year growth of 6.95%, and a net profit of 730 million CNY, up 5.41% year-on-year [2]. - The company has distributed a total of 2.04 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 10, the number of shareholders for Kanghong Pharmaceutical was 24,700, a decrease of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.21% to 27,778 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

▲成都高新区 红星新闻记者从成都高新区获悉，9月19日，成都高新区与四川发展（控股）公司合作框架协议签约仪式在成都高新区举行。 成都高新区与四川发展（控股）公司在医药健康产业方面已有深厚合作基础。2022年起，成都高新区与四川发展（控股）公司子公司四川生物医药集团开展 深度合作，聚焦化学药、医疗设备及诊断试剂、医药外包服务等重点领域开展投资布局，构建"直投+基金+园区"业务模式。后续完成了四川生物医药集团 对宏明博思药业的并购，培育赋能了成都先导、海创药业等一大批上市公司和本土明星企业。 成都高新区相关负责人表示，成都高新区将一如既往，以最大的诚意、最优的环境、最好的服务，全力助推企业做大做强，为合作项目落地见效保驾护航。 根据协议，双方将围绕医药健康产业领域的股权合作、基金组建、人才交流、创新孵化等方面展开深度合作，聚焦制药、医疗器械、医疗服务、数字医疗等 领域，创新组建产业基金、招引落地优质项目、共建孵化专业平台、引育培养人才团队，助力四川省医药健康产业不断建圈强链，推动四川省医药健康产业 高质量发展。 四川发展（控股）公司相关负责人表示，未来双方将在生物医药领域进一步加强产业合作，促进优势互补、资源共享 ...

Core Viewpoint - Kanghong Pharmaceutical experienced a 5.03% decline in stock price, closing at 37.42 CNY per share, with a total market capitalization of 34.476 billion CNY [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established on October 3, 1996, and went public on June 26, 2015. The company is located in Jin Niu District, Chengdu, Sichuan Province [1] - The main business activities include research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] Revenue Composition - The revenue composition of Kanghong Pharmaceutical is as follows: - Biological drugs: 54.83% - Traditional Chinese medicine: 32.49% - Chemical drugs: 12.50% - Others: 0.15% - Additional: 0.03% [1] Fund Holdings - CITIC Jiantou Fund has a significant holding in Kanghong Pharmaceutical, with its CITIC Jiantou Medical Health A fund (010090) holding 400,000 shares, representing 3.85% of the fund's net value [2] - The fund has reported a floating loss of approximately 792,000 CNY as of the latest update [2] Fund Performance - CITIC Jiantou Medical Health A fund was established on September 24, 2020, with a current size of 185 million CNY. Year-to-date returns are 45.86%, ranking 1208 out of 8172 in its category [2] - Over the past year, the fund has achieved a return of 52.35%, ranking 2999 out of 7980 [2] - Since inception, the fund has experienced a loss of 14.44% [2] Fund Manager Information - The fund manager of CITIC Jiantou Medical Health A is Xie Wei, who has been in the position for 7 years and 109 days. The total asset size under management is 1.987 billion CNY [2] - The best fund return during Xie Wei's tenure is 111.59%, while the worst return is -17.87% [2]

Core Viewpoint - The stock of Buchang Pharma has shown a positive trend with a year-to-date increase of 21.90%, despite a slight decline in the last five trading days [1] Group 1: Stock Performance - On September 18, Buchang Pharma's stock rose by 2.01%, reaching 19.26 CNY per share, with a trading volume of 51.29 million CNY and a turnover rate of 0.25% [1] - The total market capitalization of Buchang Pharma is 20.31 billion CNY [1] - The stock has experienced a 0.31% decline over the last five trading days, a 0.47% increase over the last 20 days, and a 19.18% increase over the last 60 days [1] Group 2: Financial Performance - For the first half of 2025, Buchang Pharma reported a revenue of 5.664 billion CNY, representing a year-on-year growth of 4.27% [2] - The net profit attributable to shareholders for the same period was 628 million CNY, showing a significant year-on-year increase of 171.24% [2] - Since its A-share listing, Buchang Pharma has distributed a total of 7.948 billion CNY in dividends, with 1.609 billion CNY distributed over the past three years [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Buchang Pharma is 55,200, a decrease of 7.32% from the previous period [2] - The average number of circulating shares per shareholder is 20,054, which has increased by 7.89% compared to the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with significant increases in their holdings [2]

Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1]. - The main business revenue composition includes: Traditional Chinese Medicine sales 53.03%, chemical drug sales 38.12%, Chinese medicinal materials and decoction pieces sales 6.13%, raw materials and intermediates sales 2.14%, and others 0.58% [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. However, the net profit attributable to the parent company was 188 million yuan, showing a significant year-on-year increase of 114.96% [2]. - Since its A-share listing, the company has distributed a total of 2.019 billion yuan in dividends, with 502 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, the stock price of Zhongsheng Pharmaceutical increased by 2.19%, reaching 20.54 yuan per share, with a total market capitalization of 17.458 billion yuan [1]. - The stock has seen a year-to-date increase of 71.88%, with a recent 5-day increase of 1.68%, a 20-day decrease of 8.95%, and a 60-day increase of 36.48% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 181 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per person, an increase of 1.33% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, while other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3].